Soluble CTLA4 molecules and uses thereof
AssigneeBristol-Myers Squibb Company
InventorsPeter S. Linsley, Jeffrey A. Ledbetter, Nitin K. Damle, William Brady, Peter A. Kiener
Life of this patent
Estimating the term…
Abstract
The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.
Claims21
An isolated soluble CTLA4 molecule the having the extracellular domain of CTLA4 which binds a B7 antigen expressed on activated B cells.
A soluble CTLA4 protein product comprising the amino acids shown in SEQ ID NO:14 beginning with alanine at position 1 and ending with aspartic acid at position 125 of the amino acid sequence of the extracellular domain of the CTLA4 protein.
A soluble CTLA4 protein product comprising the amino acids shown in SEQ ID NO:14 beginning with methionine at position 2 and ending with aspartic acid at position 125 of the amino acid sequence of the extracellular domain of the CTLA4 protein.
Dependencies are inferred from the claim text.